Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer

Endocrine-Related Cancer

Volumn 15, Issue 2, 2008, Pages 439-449

  Cappelletti, Vera ^a   Gariboldi, Manuela ^a,b   De Cecco, Loris ^a,b   Toffanin, Sara ^a   Reid, James F ^a,b   Lusa, Lara ^a,b   Bajetta, Emilio ^a   Celio, Luigi ^a   Greco, Marco ^a   Fabbri, Alessandra ^a   Pierotti, Marco A ^a,b   Daidone, Maria Grazia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLUSTERIN; ESTROGEN RECEPTOR ALPHA; GELATINASE A; MITOGEN ACTIVATED PROTEIN KINASE 14; TOREMIFENE;

ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE REGULATION; CLINICAL TRIAL; CLONE; CORRELATION ANALYSIS; DNA MICROARRAY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE SILENCING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; PREOPERATIVE TREATMENT; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR GENE; UPREGULATION;

AGED; BIOPSY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLUSTERIN; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TOREMIFENE;

EID: 45849085450     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0274     Document Type: Article

References (27)

1. Cappelletti V, Celio L, Bajetta E, Allevi A, Longarini R, Miodini P, Villa R, Fabbri A, Mariani L, Giovanazzi R et al. 2004 Prospective evaluation of estrogen receptor-β in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. Endocrine-Related Cancer 11 761-770.
2. De Cecco L, Marchionni L, Gariboldi M, Reid JF, Lagonigro MS, Caramuta S, Ferrario C, Bussani E, Mezzanzanica D, Turatti F et al. 2004 Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene 23 8171-8183.
3. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC et al. 2003 Gene profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 362-369.
4. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK et al. 2005 Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. Journal of Clinical Oncology 23 1169-1177.
5. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC & Lempicki RA 2003 DAVID: database for annotation, visualization, and integrated discovery. Genome Biology 4 P3.
6. Diehn M, Sherlock G, Binkley G, Jin H, Metese JC, Hernandez-Boussard T, Reees CA, Cherry JM, Botstein D, Brown PO et al. 2003 SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Research 31 219-223.
7. Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjorn B, Dowsett M & Eistein Lonning P 2001 Influence of neoadjuvant anastrazole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clinical Cancer Research 7 1230-1236.
8. Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, Rutgers EJ, Rodenhuis S & van de Vijver MJ 2005 Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. Journal of Clinical Oncology 23 3331-3342.
9. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, Meijervan Gelder ME, Sieuwerts AM, Portengen H, Dorssers LC et al. 2005 Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. Journal of Clinical Oncology 23 732-740.
10. Karolchik D, Baertsch R, Diekhans M, Furey TS, Hinrichs A, Lu YT, Roskin KM, Schwartz M, Sugnet CW, Thomas DJ et al. 2003 The UCSC genome browser database. Nucleic Acids Research 31 51-54.
11. Kent WJ 2002 BLAT - the BLAST-Like alignment tool. Genome Research 12 656-664.
12. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT et al. 2004 A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5 607-616.
13. Nedelcheva Kristensen V, Sorlie T, Geisler J, Yoshimura N, Linegjaerde OC, Glad I, Frigessi A, Harada N, Lonning PE & Borresen-Dale AL 2005 Effects of anastrazole on the intratumoral gene expression in locally advanced breast cancer. Journal of Steroid Biochemistry and Molecular Biology 95 105-111.
14. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer patients. New England Journal of Medicine 351 2817-2826.
15. Peto R, Boreham J, Clarke M, Davies C & Beral V 2000 UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355 1822.
16. Razandi M, Pedram A, Park ST & Levin ER 2003 Proximal events in signalling by plasma membrane estrogen receptors. Journal of Biological Chemistry 278 2701-2712.
17. R Development Core Team 2006 R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.
18. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A & Peterson C 2002 BioArray software environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biology 3 software0003.1-software0003.6.
19. Shannon B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W & Reichrath J 2006 Challenge and promise: roles for CLU in pathogenesis, progression and therapy of cancer. Cell Death and Differentiation 13 12-19.
20. Shou J, Massarweh S, Osborne CK, Wakeling Wakeling AE, Ali S, Weiss H & Schiff R 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu crosstalk in ER/HER2-positive breast cancer. Journal of the National Cancer Institute 96 926-935.
21. Simon R, Korn E, McShane L, Radmacher MD, Wright GW & Zhao Y 2003 In Design and Analysis of DNA Microarray Investigations, ch 7. New York: Springer-Verlag.
22. Simon R, Lam A, Li MC, Ngan M, Menenzes S & Zhao Y 2007 Analysis of gene expression data using BRB-Array tools. Cancer Informatics 2 11-17.
23. Stoica GE, Franke TF, Moroni M, Mueller S, Morgan E, Iann MC, Winder AD, Reiter R, Wellstein A & Martin MB 2003 Effect of estradiol on estrogen receptor-α gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 22 7998-8011.
24. Wärri AM, Huovinen RL, Laine AM, Martikainen PM & Harkonen PL 1993 Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. Journal of the National Cancer Institute 85 1412-1418.
25. Wright GW & Simon R 2003 A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19 2448-2455.
26. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J & Speed TP 2002 Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Research 3 e15.
27. Yang SX, Simon RM, Tan AR, Nguyen D & Swain SM 2005 Gene expression patterns and profile changes pre-and post-erlotinib treatment in patients with metastatic breast cancer. Clinical Cancer Research 11 6226-6232.